D. Barasa

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

D. Ettinger, V. Anagnostou, B. Levy, 2022, The oncologist.

Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes.

D. Ettinger, J. Feliciano, J. Naidoo, 2019, Journal of Clinical Oncology.